Dyne Therapeutics (DYN) Expected to Announce Earnings on Wednesday

Dyne Therapeutics (NASDAQ:DYN) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Dyne Therapeutics to post earnings of ($0.9123) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 3:00 PM ET.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts expect Dyne Therapeutics to post ($3.59) EPS for the current fiscal year and ($3.27) EPS for the next fiscal year.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $16.94 on Wednesday. Dyne Therapeutics has a 1-year low of $14.00 and a 1-year high of $27.31. The company has a 50-day moving average of $19.09 and a 200 day moving average of $19.32. The firm has a market cap of $3.16 billion, a PE ratio of -5.09 and a beta of 1.12.

Insiders Place Their Bets

In related news, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $91,190.75. Following the completion of the sale, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares of the company’s stock, valued at $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 2,598,706 shares of company stock worth $65,432,671 in the last three months. Insiders own 9.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Raymond James Financial reissued a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. Jefferies Financial Group reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Cantor Fitzgerald reissued a “buy” rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Finally, Royal Bank Of Canada cut their price objective on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.29.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.